Immunotherapy Coverage from Every Angle

Recent News

FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Merkel Cell Carcinoma
FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Melanoma
Cemiplimab-rwlc Approved for Advanced Cutaneous Squamous Cell Carcinoma in European Union
Is Immunotherapy With Cytoreductive Surgery Feasible in Metastatic Kidney Cancer?
EHA24 Congress: Selinexor With Daratumumab and Dexamethasone in Resistant Myeloma
SOPHIA Trial: Adding Margetuximab or Trastuzumab to Chemotherapy in Breast Cancer
EAGLE Trial: Novel Immunotherapies for Resistant Head/Neck Cancer
Atezolizumab Plus Bevacizumab for Sarcomatoid Metastatic Renal Cell Carcinoma
Addition of Isatuximab to Pomalidomide/Dexamethasone in Multiple Myeloma
ICML 2019: Improved Outcomes With Brentuximab Vedotin in Cutaneous Lymphoma
FDA Approves Bevacizumab Biosimilar in Nonsquamous NSCLC
ICML 2019: Mogamulizumab in Cutaneous T-Cell Lymphoma
FDA Approves Daratumumab Combination for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
EHA24 Congress: Daratumumab Plus Standard Therapy in Newly Diagnosed Myeloma
ASCO 2019: Interim Results With Neoadjuvant Atezolizumab in Resectable Lung Cancer
ASCO 2019: Final Results of KRISTINE Trial of Neoadjuvant Regimens in HER2-Positive Breast Cancer
ASCO 2019: Continued Benefit Reported With Adjvuant Ipilimumab in Resected Melanoma
ASCO 2019: Enfortumab Vedotin in Advanced Urothelial Cancer
ASCO 2019: Pembrolizumab for First-line Treatment of Unresectable Cutaneous Squamous Cell Carcinoma
New Trastuzumab Biosimilar Approved by the FDA
ASCO 2019: Phase II Basket Trial of T-DM1 in Salivary Gland Cancers
ASCO 2019: Comparing Maintenance Therapies for Nonsquamous Lung Cancer
ASCO 2019: Neoadjuvant Therapy in Melanoma: Pathologic Response and Relapse
ASCO 2019: Adding Daratumumab to Standard of Care in Transplant-Eligible Newly Diagnosed Myeloma
Pembrolizumab Approved for First-Line Treatment of Head and Neck Squamous Cell Carcinoma
ASCO 2019: Does Adding Bevacizumab to Standard Treatment Improve Survival in Urothelial Carcinoma?
ASCO 2019: Cemiplimab-rwlc in Metastatic Cutaneous Squamous Cell Carcinoma
ASCO 2019: Nivolumab Plus Ipilimumab for Symptomatic Melanoma Brain Metastases
Daratumumab Combination Therapy Granted Priority Review in Multiple Myeloma
ASCO 2019: Long-Term Survival With Pembrolizumab for Advanced NSCLC
ASCO 2019: Cemiplimab-rwlc for Locally Advanced Cutaneous Squamous Cell Carcinoma
ASCO 2019: First-Line Pembrolizumab for Metastatic Head/Neck Cancer
Evaluating Adherence to Immunomodulatory Drugs in Multiple Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.